Clinical trials
Phase 3 Recurrence trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 4 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Active, not recruiting | 13 |
| Recruiting | 11 |
| Terminated | 5 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 13 |
| Celgene | 7 |
| Biogen | 4 |
| AbbVie | 3 |
| Alexion Pharmaceuticals, Inc. | 3 |
| Amgen | 3 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 3 |
| Pfizer | 3 |
| Regeneron Pharmaceuticals | 3 |
| AstraZeneca | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 75 |
| Multiple Myeloma | 15 |
| Neoplasms | 10 |
| Multiple Sclerosis | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Lymphoma, Follicular | 6 |
| Breast Neoplasms | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Neoplasm Metastasis | 4 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.